Table 3.
Superiority and non-inferiority comparisons between the per-protocol population of each vaccine schedule group
| Poliovirus type 1 (95% CI) | Poliovirus type 2 (95% CI) | Poliovirus type 3 (95% CI) | |
|---|---|---|---|
| Non-inferiority comparisons | |||
| Two f-IPV group vs two IPV group | −2·2 (−6·3 to 1·8) | −0·8 (−4·1 to 2·6) | −12·2 (−18·4 to −6·5) |
| Two IPV group vs three IPV group | −1·9 (−5·4 to 0·3) | −1·3 (−4·5 to 0·9) | −3·1 (−7·2 to −1·0) |
| Two f-IPV group vs three f-IPV group | −2·9 (−6·8 to 0·8) | −2·1 (−5·2 to 0·3) | −9·1 (−15·7 to −2·7) |
| Three f-IPV group vs three IPV group | −1·3 (−4·4 to 0·9) | 0 (−2·9 to 2·5) | −6·3 (−11·1 to −3·4) |
| Two f-IPV group vs three IPV group | −4·1 (−7·9 to −1·9) | −2·1 (−5·2 to 0·1) | −15·4 (−21·1 to −11·0) |
| Three f-IPV group vs two IPV group | 0·6 (−2·8 to 4·3) | 1·3 (−1·1 to 4·5) | −3·1 (−8·4 to 1·7) |
| Superiority comparisons | |||
| Two IPV group vs three IPV group after two doses | 2·6 (−1·5 to 6·9) | 9·9 (5·2 to 15·5)† | 3·0 (−1·8 to 7·9) |
| Two f-IPV group vs three f-IPV group after two doses | 12·7 (6·6 to 19·6)† | 14·1 (8·6 to 20·8)† | 11·3 (2·9 to 20·0)‡ |
The three IPV group received intramuscular vaccine at 10, 14, and 36 weeks. The two IPV group received intramuscular vaccine at 14 and 36 weeks. The three f-IPV group received intradermal vaccine at 10, 14, and 36 weeks. The two f-IPV group received intradermal vaccine at 14 and 36 weeks.
*Using values at 18 weeks for the three dose regimens, 4 weeks after administration of second dose.
†
p<0·0001.
‡
p=0·0062.